Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

rituximab

Gilead Sciences

Gilead steps into breach left by AbbVie as Galapagos’ partner

Deal worth $2bn to help rheumatoid arthritis drug filgotinib make it through to the market

- PMLiVE

NHS patients set to be denied Opdivo and Kadcyla

NICE rejects BMS and Roche cancer treatments

Roche Basel Switzerland

Roche’s lung cancer drug Alecensa gets FDA OK

Wins accelerated US approval for non-small cell lung cancer

- PMLiVE

Novel therapies for blood cancers showcased at ASH

Novartis' lead CAR-T therapy is one of those in the spotlight

Roche - Basel

Roche drops superbug partnership with Polyphor

But adds inflammation research agreement with Proximagen

- PMLiVE

Lucid behavioural change programmes recognised at PMEA

Agency wins awards for initiatives for AbbVieand Genzyme

Roche Basel Switzerland

Roche gets EU green light for Cotellic

Approved in combination with Zelboraf for melanoma

- PMLiVE

AbbVie takes Company of the Year at PMEA 2015

Firm rewarded for patient-centricity, whileAstellas is highly commended

Roche Basel Switzerland

Roche posts positive Cotellic data ahead of anticipated EU approval

Comes after FDA and Swiss approvals and CHMPrecommendation

Roche Basel Switzerland

Roche exits four manufacturing sites with loss of 1,200 jobs

Closes three Europeans plants and one US facility

- PMLiVE

FDA approves Exelixis/Genentech’s melanoma combo Cotellic

Willprovide the first direct competition to Novartis' Mekinist in the US

- PMLiVE

Amgen’s biosimilar shows clinical equivalence with Humira

ABP 501 as effective as AbbVie's blockbuster in phase III rheumatoid arthritis trial

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links